<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02398604</url>
  </required_header>
  <id_info>
    <org_study_id>20140718</org_study_id>
    <nct_id>NCT02398604</nct_id>
  </id_info>
  <brief_title>Allogeneic hMSC Injection in Patients With Hypoplastic Left Heart Syndrome</brief_title>
  <acronym>ELPIS</acronym>
  <official_title>Allogeneic Human MEsenchymal Stem Cell (hMSC) Injection in Patients With Hypoplastic Left Heart Syndrome: An Open Label Pilot Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joshua M Hare</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Maryland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is intended to evaluate the safety and feasibility of intramyocardial injection of
      allogeneic mesenchymal cells during the Bi-Directional Cavopulmonary Anastomosis (BDCPA)
      surgery for hypoplastic left heart syndrome (HLHS) pediatric patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label study, intended as a safety and efficacy assessment prior to a full
      comparator study. In this Phase I study, cells administered will be delivered in 6-10
      intramyocardial injections that will be tested in 20 patients and 10 patients will be
      controls with a total of 30 HLHS patients.

      A total of 30 patients with HLHS will be enrolled in a staged enrollment process. In this
      open-labeled study, a maximum of 20 patients will eventually receive intramyocardial
      injection of the allogeneic mesenchymal stem cells and 10 control patients with no cell
      injection. The enrollment of the patients will occur in two stages groups: Group A and Group
      B. In Group A, 10 consecutive HLHS patients will be initially enrolled in the allogenic MSCs
      treatment arm to determine feasibility and safety. After 6 months of the last enrolled
      patient in Group A, all Group A patients will be assessed in order to determine whether it is
      feasible and safe, including the harvesting, processing, and administering of the allogeneic
      MSCs. Thereafter, Group B will start enrolling a total of 20 HLHS patients which will be
      randomized to the treatment and control arms in a 1:1 ratio, respectively, in order to have
      10 allogeneic MSCs-treated patient and 10 control patients. At the completion of this Phase I
      clinical study, the total enrolled cohort will be 20 patients treated with allogeneic MSCs
      and 10 patients in the control arm.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>20 patients and 10 patients will be controls with a total of 30 HLHS patients.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>HLHS patients which will be randomized to the treatment and control arms in a 1:1 ratio</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Monitor major adverse cardiac events</measure>
    <time_frame>1 month after injection</time_frame>
    <description>Monitoring of events includes death, sustained/symptomatic ventricular tachycardia requiring intervention with inotropic support, aggravation of heart failure, new myocardial infarction, unplanned cardiovascular operation for cardiac tamponade and infection in the first month after injection, and serially afterwards.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite Change from baseline in right ventricular function, right ventricular end-diastolic volume, right ventricular end-systolic volume, right ventricular end-systolic diameter and tricuspid regurgitation</measure>
    <time_frame>baseline, 24 weeks and 1 year</time_frame>
    <description>as measured by serial echocardiograms and MRI scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with incidence of mortality or need for transplantation after the BDCPA operation</measure>
    <time_frame>One year after injections</time_frame>
    <description>Assessed through the number of participants with adverse events, hospitalizations, or transplantations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Changes in somatic growth velocity over time (weight, height, head circumference) from the BDCPA operation</measure>
    <time_frame>12 months post operative</time_frame>
    <description>Changes in weight, height, and head circumference will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Co-morbidity</measure>
    <time_frame>up to 12 months follow-up</time_frame>
    <description>Assessment of cardiovascular mortality, all-cause morbidity, Cardiovascular morbidity, re-hospitalizations, need for transplantation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hypoplastic Left Heart Syndrome</condition>
  <arm_group>
    <arm_group_label>Group A - Allo-hMSCs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group A: Fifteen (20) patients will be treated with Allogenic human mesenchymal stem cells (Allo-hMSCs): A concentration of 5 million cells/ml delivered in a dose of 2.5 x 10^5 cells per kg of recipient (5 million/20kg) Allo-hMSCs. The entire dose of the cells will be divided and delivered in 6-10 open intramyocardial injections during the BDCPA operation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group B: Fifteen (10) patients will be treated with a placebo comparator. The placebo will be divided and delivered in 6-10 open intramyocardial injections during the BDCPA operation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allo-hMSCs</intervention_name>
    <description>Allogeneic Human Mesenchymal Stem Cells</description>
    <arm_group_label>Group A - Allo-hMSCs</arm_group_label>
    <other_name>stem cells; Allogeneic Human Mesenchymal Stem Cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Group B</arm_group_label>
    <other_name>Placebo comparator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with hypoplastic left heart syndrome (all types) requiring BDCPA surgery.

        Exclusion Criteria:

          -  Have HLHS and restrictive or intact atrial septum.

          -  Be undergoing the Norwood procedure that do not have HLHS.

          -  Have significant coronary artery sinusoids.

          -  Require mechanical circulatory support prior to surgery.

          -  Have an underlying evidence of arrhythmia requiring anti-arrhythmia therapy.

          -  Parent or guardian unwilling or unable to comply with necessary follow-up(s)

          -  Be serum positive for HIV, hepatitis BsAg or viremic hepatitis C.

          -  Be unsuitable for inclusion in the study, in the opinion of the investigator.

          -  Need for concomitant surgery for aortic coarctation or tricuspid valve repair.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>30 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sunjay Kaushal, MD, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joshua M Hare, MD</last_name>
    <phone>305-243-5579</phone>
    <email>jhare@med.miami.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sunjay Kaushal, MD</last_name>
    <phone>410-328-0061</phone>
    <email>SKaushal@som.umaryland.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sunjay Kaushal, MD, PhD</last_name>
      <phone>410-328-5842</phone>
      <email>skaushal@smail.umaryland.edu</email>
    </contact>
    <contact_backup>
      <last_name>Helina Mehta</last_name>
      <phone>410-328-2750</phone>
      <email>HGMehta@som.umaryland.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Sunjay Kaushal, MD, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naru Hibino, MD</last_name>
      <phone>410-955-2800</phone>
      <email>nhibino1@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>William Ravekes, MD</last_name>
      <phone>410-955-5987</phone>
      <email>wravekes@jhmi.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Narutishi Hibino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://isci.med.miami.edu</url>
    <description>Interdisciplinary Stem Cell Institute</description>
  </link>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 24, 2014</study_first_submitted>
  <study_first_submitted_qc>March 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2015</study_first_posted>
  <last_update_submitted>November 21, 2017</last_update_submitted>
  <last_update_submitted_qc>November 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Joshua M Hare</investigator_full_name>
    <investigator_title>Sponsor</investigator_title>
  </responsible_party>
  <keyword>Pediatrics</keyword>
  <keyword>HLHS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Hypoplastic Left Heart Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

